Increased Expressions of Programmed Death Ligand 1 and Galectin 9 in Transplant Recipients Who Achieved Tolerance After Immunosuppression Withdrawal.

B7-H1 Antigen / analysis Child Forkhead Transcription Factors / analysis Galectins / metabolism Humans Immunosuppression Therapy / adverse effects Ligands Liver Transplantation / adverse effects Transplant Recipients

Journal

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

ISSN: 1527-6473

Titre abrégé: Liver Transpl

Pays: United States

ID NLM: 100909185

Informations de publication

Date de publication:
04 2022

Historique:

revised: 27 09 2021

received: 21 08 2021

accepted: 06 10 2021

pubmed: 17 10 2021

medline: 26 4 2022

entrez: 16 10 2021

Statut: ppublish

Résumé

Programmed death 1 (PD1)/its ligand PD-L1 concomitant with T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)/its ligand galectin 9 (Gal-9) and the forkhead box P3 (FOXP3) might be involved in tolerance after liver transplantation (LT). Liver biopsies from 38 tolerant, 19 nontolerant (including 16 samples that triggered reintroduction of immunosuppression [IS] and 19 samples after IS reintroduction), and 38 control LT patients were studied. The expressions of PD1, PD-L1, Gal-9, and FOXP3 were determined by immunohistochemical and immunofluorescence (IF) staining. The success period of IS withdrawal was calculated using Kaplan-Meier curve analysis. Tolerant and control patients exhibited higher PD-L1, Gal-9, and FOXP3 levels than nontolerant patients at the moment of triggering IS reintroduction. High expressions of PD-L1 and Gal-9 were associated with prolonged success of tolerance (83.3% versus 36.7% [P < 0.01] and 73.1% versus 42.9% [P = 0.03]). A strong correlation between PD-L1 and Gal-9 expression levels was detected (Spearman r = 0.73; P ≤ 0.001), and IF demonstrated colocalization of PD-L1 and Gal-9 in the cytoplasm of hepatocytes. In conclusion, the present study demonstrated that increased expressions of PD-L1 and Gal-9 were associated with sustained tolerance after IS withdrawal in pediatric liver transplantation.

Identifiants

DOI: 10.1002/lt.26336 PMID: 34655506

pubmed: 34655506

doi: 10.1002/lt.26336

pii: 01445473-202204000-00022

doi:

Substances chimiques

B7-H1 Antigen 0

Forkhead Transcription Factors 0

Galectins 0

Ligands 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

647-658

Informations de copyright

Références

Singh S, Watt KD. Long‐term medical management of the liver transplant recipient: what the primary care physician needs to know. Mayo Clin Proc 2012;87:779–790.

Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011;306:1891–1901.

Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931–940.

Burra P, Rodriguez‐Castro KI. Neoplastic disease after liver transplantation: focus on de novo neoplasms. World J Gastroenterol 2015;21:8753–8768.

Benítez C, Londoño M‐C, Miquel R, Manzia T‐M, Abraldes JG, Lozano J‐J, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013;58:1824–1835.

Pons JA, Ramírez P, Revilla‐Nuin B, Pascual D, Baroja‐Mazo A, Robles R, et al. Immunosuppression withdrawal improves long‐term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant 2009;23:329–336.

de la Garza RG, Sarobe P, Merino J, Lasarte JJ, D'Avola D, Belsue V, et al. Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl 2013;19:937–944.

Lin N‐C, Wang H‐K, Yeh Y‐C, Liu C‐P, Loong C‐C, Tsai H‐L, et al. Minimization or withdrawal of immunosuppressants in pediatric liver transplant recipients. J Pediatr Surg 2015;50:2128–2133.

Levitsky J, Burrell BE, Kanaparthi S, Turka LA, Kurian S, Sanchez‐Fueyo A, et al. Immunosuppression withdrawal in liver transplant recipients on sirolimus. Hepatology 2020;72:569–583.

Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887–3895.

Okazaki T, Honjo T. PD‐1 and PD‐1 ligands: from discovery to clinical application. Int Immunol 2007;19:813–824.

Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD‐1 signaling pathway. J Biomed Sci 2017;24:26.

Tanaka K, Albin MJ, Yuan X, Yamaura K, Habicht A, Murayama T, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007;179:5204–5210.

Okazaki T, Honjo T. The PD‐1–PD‐L pathway in immunological tolerance. Trends Immunol 2006;27:195–201.

Friend BD, Venick RS, McDiarmid SV, Zhou X, Naini B, Wang H, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer 2017;64:e26682.

Gassmann D, Weiler S, Mertens JC, Reiner CS, Vrugt B, Nägeli M, et al. Liver allograft failure after nivolumab treatment—a case report with systematic literature research. Transplant Direct 2018;4:e376.

DeLeon TT, Salomao MA, Aqel BA, Sonbol MB, Yokoda RT, Ali AH, et al. Pilot evaluation of PD‐1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol 2018;9:1054–1062.

Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J 2018;6:970–973.

Zhang A‐B, Peng Y‐F, Jia J‐J, Nie YU, Zhang S‐Y, Xie H‐Y, et al. Exosome‐derived galectin‐9 may be a novel predictor of rejection and prognosis after liver transplantation. J Zhejiang Univ Sci B 2019;20:605–612.

Sideras K, de Man RA, Harrington SM, Polak WG, Zhou G, Schutz HM, et al. Circulating levels of PD‐L1 and Galectin‐9 are associated with patient survival in surgically treated hepatocellular carcinoma independent of their intra‐tumoral expression levels. Sci Rep 2019;9:10677.

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim‐3 and PD‐1 expression is associated with tumor antigen‐specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175–2186.

Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim‐3 and PD‐1 pathways to reverse T cell exhaustion and restore anti‐tumor immunity. J Exp Med 2010;207:2187–2194.

Abe Y, Urakami H, Ostanin D, Zibari G, Hayashida T, Kitagawa Y, Grisham MB. Induction of Foxp3‐expressing regulatory T‐cells by donor blood transfusion is required for tolerance to rat liver allografts. PLoS One 2009;4:e7840.

Qi H, Chen G, Huang Y, Si Z, Li J. Foxp3‐modified bone marrow mesenchymal stem cells promotes liver allograft tolerance through the generation of regulatory T cells in rats. J Transl Med 2015;13:274.

Koshiba T, Li Y, Takemura M, Wu Y, Sakaguchi S, Minato N, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living‐donor liver transplantation. Transpl Immunol 2007;17:94–97.

Anthony JD, Kenneth PB, Amar PD, Linda F, John F, Stephen AG, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658–663.

Ohe H, Waki K, Yoshitomi M, Morimoto T, Nafady‐Hego H, Satoda N, et al. Factors affecting operational tolerance after pediatric living‐donor liver transplantation: impact of early post‐transplant events and HLA match*. Transpl Int 2012;25:97–106.

Pinato DJ, Mauri FA, Spina P, Cain O, Siddique A, Goldin R, et al. Clinical implications of heterogeneity in PD‐L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint‐HCC study. Br J Cancer 2019;120:1033–1036.

Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology 2016;64:2038–2046.

Wang B‐J, Bao J‐J, Wang J‐Z, Wang Y, Jiang M, Xing M‐Y, et al. Immunostaining of PD‐1/PD‐Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 2011;17:3322–3329.

Shi X‐L, Mancham S, Hansen BE, de Knegt RJ, de Jonge J, van der Laan LJW, et al. Counter‐regulation of rejection activity against human liver grafts by donor PD‐L1 and recipient PD‐1 interaction. J Hepatol 2016;64:1274–1282.

Wang Y, Wang H, Yao H, Li C, Fang J‐Y, Xu J. Regulation of PD‐L1: emerging routes for targeting tumor immune evasion. Front Pharmacol 2018;9:536.

Morita M, Fujino M, Jiang G, Kitazawa Y, Xie L, Azuma M, et al. PD‐1/B7‐H1 interaction contribute to the spontaneous acceptance of mouse liver allograft. Am J Transplant 2010;10:40–46.

Tokita D, Mazariegos GV, Zahorchak AF, Chien N, Abe M, Raimondi G, Thomson AW. High PD‐L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T‐regulatory cells in liver transplant tolerance. Transplantation 2008;85:369–377. https://journals.lww.com/transplantjournal/Fulltext/2008/02150/High_PD_L1_CD86_Ratio_on_Plasmacytoid_Dendritic.11.aspx . Accessed June 02, 2021.

Gu D, Ao X, Yang YU, Chen Z, Xu X. Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer 2018;6:132.

Zhu X, Lang J. Soluble PD‐1 and PD‐L1: predictive and prognostic significance in cancer. Oncotarget 2017;8:57. https://www.oncotarget.com/article/18311/text/ . Accessed December 31, 2016.

Mengshol JA, Golden‐Mason L, Arikawa T, Smith M, Niki T, McWilliams R, et al. A crucial role for Kupffer cell‐derived galectin‐9 in regulation of T cell immunity in hepatitis C infection. PLoS One 2010;5:e9504.